Objective: This study explored the differences in cognitive emotion regulation strategies, body image, and sexual functioning between women with breast cancer and healthy controls. It also investigated the relationships among these variables in breast cancer patients, considering the role of depression and anxiety. Methods: This cross-sectional case-control study included 112 participants (56 breast cancer patients and 56 healthy controls). Participants were assessed using the Cognitive Emotion Regulation Questionnaire, Body Cathexis Scale, Female Sexual Function Index (FSFI), and Golombok Rust Inventory of Sexual Satisfaction (GRISS). Depression and anxiety levels were evaluated using the Hamilton Depression Rating Scale and Hamilton Anxiety Scale. Statistical analyses included group comparisons and partial correlation analyses. Results: Breast cancer patients exhibited significantly higher scores on the depression scale, reflecting greater depressive symptoms, poorer body image, and greater impairments in sexual functioning compared to healthy controls. GRISS subscales indicated higher dissatisfaction, avoidance, nonsensuality, vaginismus, and anorgasmia in breast cancer patients, while FSFI subscales showed reduced desire, arousal, lubrication, satisfaction, and orgasm. Positive reappraisal, an adaptive cognitive emotion regulation strategy, was negatively associated with sexual dissatisfaction after controlling for depression and anxiety. Conclusion Breast cancer significantly impacts mental health, body image, and sexual functioning. The findings underscore the importance of integrating psychiatric screening and care into oncology. Interventions enhancing cognitive emotion regulation, particularly positive reappraisal, may improve psychological and sexual well-being in breast cancer survivors.

Objective: This study explored the differences in cognitive emotion regulation strategies, body image, and sexual functioning between women with breast cancer and healthy controls. It also investigated the relationships among these variables in breast cancer patients, considering the role of depression and anxiety. Methods: This cross-sectional case-control study included 112 participants (56 breast cancer patients and 56 healthy controls). Participants were assessed using the Cognitive Emotion Regulation Questionnaire, Body Cathexis Scale, Female Sexual Function Index (FSFI), and Golombok Rust Inventory of Sexual Satisfaction (GRISS). Depression and anxiety levels were evaluated using the Hamilton Depression Rating Scale and Hamilton Anxiety Scale. Statistical analyses included group comparisons and partial correlation analyses. Results: Breast cancer patients exhibited significantly higher scores on the depression scale, reflecting greater depressive symptoms, poorer body image, and greater impairments in sexual functioning compared to healthy controls. GRISS subscales indicated higher dissatisfaction, avoidance, nonsensuality, vaginismus, and anorgasmia in breast cancer patients, while FSFI subscales showed reduced desire, arousal, lubrication, satisfaction, and orgasm. Positive reappraisal, an adaptive cognitive emotion regulation strategy, was negatively associated with sexual dissatisfaction after controlling for depression and anxiety. Conclusion Breast cancer significantly impacts mental health, body image, and sexual functioning. The findings underscore the importance of integrating psychiatric screening and care into oncology. Interventions enhancing cognitive emotion regulation, particularly positive reappraisal, may improve psychological and sexual well-being in breast cancer survivors.

Objective: This study explored the differences in cognitive emotion regulation strategies, body image, and sexual functioning between women with breast cancer and healthy controls. It also investigated the relationships among these variables in breast cancer patients, considering the role of depression and anxiety. Methods: This cross-sectional case-control study included 112 participants (56 breast cancer patients and 56 healthy controls). Participants were assessed using the Cognitive Emotion Regulation Questionnaire, Body Cathexis Scale, Female Sexual Function Index (FSFI), and Golombok Rust Inventory of Sexual Satisfaction (GRISS). Depression and anxiety levels were evaluated using the Hamilton Depression Rating Scale and Hamilton Anxiety Scale. Statistical analyses included group comparisons and partial correlation analyses. Results: Breast cancer patients exhibited significantly higher scores on the depression scale, reflecting greater depressive symptoms, poorer body image, and greater impairments in sexual functioning compared to healthy controls. GRISS subscales indicated higher dissatisfaction, avoidance, nonsensuality, vaginismus, and anorgasmia in breast cancer patients, while FSFI subscales showed reduced desire, arousal, lubrication, satisfaction, and orgasm. Positive reappraisal, an adaptive cognitive emotion regulation strategy, was negatively associated with sexual dissatisfaction after controlling for depression and anxiety. Conclusion Breast cancer significantly impacts mental health, body image, and sexual functioning. The findings underscore the importance of integrating psychiatric screening and care into oncology. Interventions enhancing cognitive emotion regulation, particularly positive reappraisal, may improve psychological and sexual well-being in breast cancer survivors.

Objective: This study explored the differences in cognitive emotion regulation strategies, body image, and sexual functioning between women with breast cancer and healthy controls. It also investigated the relationships among these variables in breast cancer patients, considering the role of depression and anxiety. Methods: This cross-sectional case-control study included 112 participants (56 breast cancer patients and 56 healthy controls). Participants were assessed using the Cognitive Emotion Regulation Questionnaire, Body Cathexis Scale, Female Sexual Function Index (FSFI), and Golombok Rust Inventory of Sexual Satisfaction (GRISS). Depression and anxiety levels were evaluated using the Hamilton Depression Rating Scale and Hamilton Anxiety Scale. Statistical analyses included group comparisons and partial correlation analyses. Results: Breast cancer patients exhibited significantly higher scores on the depression scale, reflecting greater depressive symptoms, poorer body image, and greater impairments in sexual functioning compared to healthy controls. GRISS subscales indicated higher dissatisfaction, avoidance, nonsensuality, vaginismus, and anorgasmia in breast cancer patients, while FSFI subscales showed reduced desire, arousal, lubrication, satisfaction, and orgasm. Positive reappraisal, an adaptive cognitive emotion regulation strategy, was negatively associated with sexual dissatisfaction after controlling for depression and anxiety. Conclusion Breast cancer significantly impacts mental health, body image, and sexual functioning. The findings underscore the importance of integrating psychiatric screening and care into oncology. Interventions enhancing cognitive emotion regulation, particularly positive reappraisal, may improve psychological and sexual well-being in breast cancer survivors.

Objective: This study explored the differences in cognitive emotion regulation strategies, body image, and sexual functioning between women with breast cancer and healthy controls. It also investigated the relationships among these variables in breast cancer patients, considering the role of depression and anxiety. Methods: This cross-sectional case-control study included 112 participants (56 breast cancer patients and 56 healthy controls). Participants were assessed using the Cognitive Emotion Regulation Questionnaire, Body Cathexis Scale, Female Sexual Function Index (FSFI), and Golombok Rust Inventory of Sexual Satisfaction (GRISS). Depression and anxiety levels were evaluated using the Hamilton Depression Rating Scale and Hamilton Anxiety Scale. Statistical analyses included group comparisons and partial correlation analyses. Results: Breast cancer patients exhibited significantly higher scores on the depression scale, reflecting greater depressive symptoms, poorer body image, and greater impairments in sexual functioning compared to healthy controls. GRISS subscales indicated higher dissatisfaction, avoidance, nonsensuality, vaginismus, and anorgasmia in breast cancer patients, while FSFI subscales showed reduced desire, arousal, lubrication, satisfaction, and orgasm. Positive reappraisal, an adaptive cognitive emotion regulation strategy, was negatively associated with sexual dissatisfaction after controlling for depression and anxiety. Conclusion Breast cancer significantly impacts mental health, body image, and sexual functioning. The findings underscore the importance of integrating psychiatric screening and care into oncology. Interventions enhancing cognitive emotion regulation, particularly positive reappraisal, may improve psychological and sexual well-being in breast cancer survivors.

Objective: : This animal model aimed to compare the rat group that received brain irradiation and did not receive additional treatment (only saline) and the rat group that underwent brain irradiation and received Granulocyte colony stimulating factor (G-CSF) treatment. In addition, the effects of G-CSF on brain functions were examined by magnetic resonance (MR) imaging and histopathologically. Methods: : This study used 24 female Wistar albino rats. Drug administration (saline or G-CSF) was started at the beginning of the study and continued for 15 days after whole-brain radiotherapy (WBRT). WBRT was given on day 7 of the start of the study. At the end of 15 days, the behavioral tests, including the three-chamber sociability test, open field test, and passive avoidance learning test, were done. After the behavioral test, the animals performed the MR spectroscopy procedure. At the end of the study, cervical dislocation was applied to all animals. Results: : G-CSF treatment positively affected the results of the three-chamber sociability test, open-space test and passive avoidance learning test, cornu Ammonis (CA) 1, CA3, and Purkinje neuron counts, and the brain levels of brain-derived neurotrophic factor and postsynaptic density protein-95. However, G-CSF treatment reduced the glial fibrillary acidic protein immunostaining index and brain levels of malondialdehyde, tumor necrosis factor-alpha, nuclear factor kappa-B, and lactate. In addition, on MR spectroscopy, G-CSF had a reversible effect on brain lactate levels. Conclusion : In this first designed brain irradiation animal model, which evaluated G-CSF effects, we observed that G-CSF had reparative, neuroprotective and anti-neurodegenerative effects and had increased neurotrophic factor expression, neuronal counts, and morphology changes. In addition, G-CSF had a proven lactate-lowering effect in MR spectroscopy and brain materials.

Objective: To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT). Methods: A 322 patients whose final pathologic outcome was AGCT treated at nine tertiary oncology centers between 1988 and 2021 participated in the study. Results: The mean age of the patients was 51.3±11.8 years and ranged from 21 to 82 years.According to the International Federation of Gynecology and Obstetrics 2014, 250 (77.6%) patients were stage I, 24 (7.5%) patients were stage II, 20 (6.2%) patients were stage III, and 3 (7.8%) were stage IV. Lymphadenectomy was added to the surgical procedure in 210(65.2%) patients. Lymph node involvement was noted in seven (3.3%) patients. Peritoneal cytology was positive in 19 (5.9%) patients, and 13 (4%) had metastases in the omentum. Of 285 patients who underwent hysterectomy, 19 (6.7%) had complex hyperplasia with atypia/ endometrial intraepithelial neoplasia, and 8 (2.8%) had grade 1 endometrioid endometrial carcinoma. It was found that 93 (28.9%) patients in the study group received adjuvant treatment. Bleomycin, etoposide, cisplatin was the most commonly used chemotherapy protocol. The median follow-up time of the study group was 41 months (range, 1–276months). It was noted that 34 (10.6%) patients relapsed during this period, and 9 (2.8%)patients died because of the disease. The entire cohort had a 5-year disease-free survival (DFS) of 86% and a 5-year disease-specific survival of 98%. Recurrences were observed only in the pelvis in 13 patients and the extra-abdominal region in 7 patients. The recurrence rate increased 6.168-fold in patients with positive peritoneal cytology (95% confidence interval [CI]=1.914–19.878; p=0.002), 3.755-fold in stage II–IV (95% CI=1.275–11.063; p=0.016), and 2.517-fold in postmenopausal women (95% CI=1.017–6.233; p=0.046) increased. Conclusion In this study, lymph node involvement was detected in 3.3% of patients with AGCT. Therefore, it was concluded that lymphadenectomy can be avoided in primary surgical treatment. Positive peritoneal cytology, stage, and menopausal status were independent prognostic predictors of DFS.

Objective: To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT). Methods: A 322 patients whose final pathologic outcome was AGCT treated at nine tertiary oncology centers between 1988 and 2021 participated in the study. Results: The mean age of the patients was 51.3±11.8 years and ranged from 21 to 82 years.According to the International Federation of Gynecology and Obstetrics 2014, 250 (77.6%) patients were stage I, 24 (7.5%) patients were stage II, 20 (6.2%) patients were stage III, and 3 (7.8%) were stage IV. Lymphadenectomy was added to the surgical procedure in 210(65.2%) patients. Lymph node involvement was noted in seven (3.3%) patients. Peritoneal cytology was positive in 19 (5.9%) patients, and 13 (4%) had metastases in the omentum. Of 285 patients who underwent hysterectomy, 19 (6.7%) had complex hyperplasia with atypia/ endometrial intraepithelial neoplasia, and 8 (2.8%) had grade 1 endometrioid endometrial carcinoma. It was found that 93 (28.9%) patients in the study group received adjuvant treatment. Bleomycin, etoposide, cisplatin was the most commonly used chemotherapy protocol. The median follow-up time of the study group was 41 months (range, 1–276months). It was noted that 34 (10.6%) patients relapsed during this period, and 9 (2.8%)patients died because of the disease. The entire cohort had a 5-year disease-free survival (DFS) of 86% and a 5-year disease-specific survival of 98%. Recurrences were observed only in the pelvis in 13 patients and the extra-abdominal region in 7 patients. The recurrence rate increased 6.168-fold in patients with positive peritoneal cytology (95% confidence interval [CI]=1.914–19.878; p=0.002), 3.755-fold in stage II–IV (95% CI=1.275–11.063; p=0.016), and 2.517-fold in postmenopausal women (95% CI=1.017–6.233; p=0.046) increased. Conclusion In this study, lymph node involvement was detected in 3.3% of patients with AGCT. Therefore, it was concluded that lymphadenectomy can be avoided in primary surgical treatment. Positive peritoneal cytology, stage, and menopausal status were independent prognostic predictors of DFS.

Objective: To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT). Methods: A 322 patients whose final pathologic outcome was AGCT treated at nine tertiary oncology centers between 1988 and 2021 participated in the study. Results: The mean age of the patients was 51.3±11.8 years and ranged from 21 to 82 years.According to the International Federation of Gynecology and Obstetrics 2014, 250 (77.6%) patients were stage I, 24 (7.5%) patients were stage II, 20 (6.2%) patients were stage III, and 3 (7.8%) were stage IV. Lymphadenectomy was added to the surgical procedure in 210(65.2%) patients. Lymph node involvement was noted in seven (3.3%) patients. Peritoneal cytology was positive in 19 (5.9%) patients, and 13 (4%) had metastases in the omentum. Of 285 patients who underwent hysterectomy, 19 (6.7%) had complex hyperplasia with atypia/ endometrial intraepithelial neoplasia, and 8 (2.8%) had grade 1 endometrioid endometrial carcinoma. It was found that 93 (28.9%) patients in the study group received adjuvant treatment. Bleomycin, etoposide, cisplatin was the most commonly used chemotherapy protocol. The median follow-up time of the study group was 41 months (range, 1–276months). It was noted that 34 (10.6%) patients relapsed during this period, and 9 (2.8%)patients died because of the disease. The entire cohort had a 5-year disease-free survival (DFS) of 86% and a 5-year disease-specific survival of 98%. Recurrences were observed only in the pelvis in 13 patients and the extra-abdominal region in 7 patients. The recurrence rate increased 6.168-fold in patients with positive peritoneal cytology (95% confidence interval [CI]=1.914–19.878; p=0.002), 3.755-fold in stage II–IV (95% CI=1.275–11.063; p=0.016), and 2.517-fold in postmenopausal women (95% CI=1.017–6.233; p=0.046) increased. Conclusion In this study, lymph node involvement was detected in 3.3% of patients with AGCT. Therefore, it was concluded that lymphadenectomy can be avoided in primary surgical treatment. Positive peritoneal cytology, stage, and menopausal status were independent prognostic predictors of DFS.